Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。
研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。
Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。
研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.